<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD03050000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P08913</UniProt_ID>
  <Seq_Length>450</Seq_Length>
  <Molecule_Weight>48957</Molecule_Weight>
  <KEGG_ID>hsa:150</KEGG_ID>
  <Orthology_ID>K04138</Orthology_ID>
  <Function_Summary>Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline </Function_Summary>
  <Pfam_ID>PF00001:7tm_1</Pfam_ID>
  <Allosteric_Activator_Count>3</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>1</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>Alpha-2A adrenoceptor</Alias>
      <Alias>Alpha-2AAR subtype C10</Alias>
      <Alias>Alpha-2A adrenoreceptor</Alias>
      <Alias>Alpha-2-adrenergic receptor, platelet type</Alias>
      <Alias>Alpha-2 adrenergic receptor subtype C10</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with an identical protein to form a homodimer.</Detail>
      <Keyword>Protein homodimerization activity</Keyword>
      <Ontology_ID>GO:0042803</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with an alpha-1B adrenergic receptor.</Detail>
      <Keyword>Alpha-1B adrenergic receptor binding</Keyword>
      <Ontology_ID>GO:0031692</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a nonidentical protein to form a heterodimer.</Detail>
      <Keyword>Protein heterodimerization activity</Keyword>
      <Ontology_ID>GO:0046982</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with norepinephrine, (3,4-dihydroxyphenyl-2-aminoethanol), a hormone secreted by the adrenal medulla and a neurotransmitter in the sympathetic peripheral nervous system and in some tracts of the CNS. It is also the biosynthetic precursor of epinephrine.</Detail>
      <Keyword>Norepinephrine binding</Keyword>
      <Ontology_ID>GO:0051380</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with an alpha-2C adrenergic receptor.</Detail>
      <Keyword>Alpha-2C adrenergic receptor binding</Keyword>
      <Ontology_ID>GO:0031696</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a protein kinase, any enzyme that catalyzes the transfer of a phosphate group, usually from ATP, to a protein substrate.</Detail>
      <Keyword>Protein kinase binding</Keyword>
      <Ontology_ID>GO:0019901</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with an extracellular or intracellular messenger to initiate a change in cell activity.</Detail>
      <Keyword>Receptor activity</Keyword>
      <Ontology_ID>GO:0004872</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with epinephrine or norepinephrine to initiate a change in cell activity via activation of a G protein, with pharmacological characteristics of alpha2-adrenergic receptors; the activity involves transmitting the signal to the Gi alpha subunit of a heterotrimeric G protein.</Detail>
      <Keyword>Alpha2-adrenergic receptor activity</Keyword>
      <Ontology_ID>GO:0004938</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with epinephrine, a hormone produced by the medulla of the adrenal glands that increases heart activity, improves the power and prolongs the action of muscles, and increases the rate and depth of breathing. It is synthesized by the methylation of norepinephrine.</Detail>
      <Keyword>Epinephrine binding</Keyword>
      <Ontology_ID>GO:0051379</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a heterotrimeric G-protein.</Detail>
      <Keyword>Heterotrimeric G-protein binding</Keyword>
      <Ontology_ID>GO:0032795</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any thioesterase enzyme.</Detail>
      <Keyword>Thioesterase binding</Keyword>
      <Ontology_ID>GO:0031996</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>401</Position>
      <Original>Cys</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>251</Position>
      <Original>Asn</Original>
      <Variation>Lys</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of cell migration.</Detail>
      <Keyword>Positive regulation of cell migration</Keyword>
      <Ontology_ID>GO:0030335</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the rate or extent of cell proliferation.</Detail>
      <Keyword>Positive regulation of cell proliferation</Keyword>
      <Ontology_ID>GO:0008284</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of membrane protein ectodomain peptidolysis.</Detail>
      <Keyword>Positive regulation of membrane protein ectodomain proteolysis</Keyword>
      <Ontology_ID>GO:0051044</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals generated as a consequence of an adrenergic receptor binding to its physiological ligand, followed by the activation of phospholipase C and the subsequent release of inositol trisphosphate.</Detail>
      <Keyword>Activation of phospholipase C activity by adrenergic receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0071882</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways by which a cell derives energy from stored compounds such as fats or glycogen.</Detail>
      <Keyword>Energy reserve metabolic process</Keyword>
      <Ontology_ID>GO:0006112</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process in which nutrients are taken up from the contents of the intestine.</Detail>
      <Keyword>Intestinal absorption</Keyword>
      <Ontology_ID>GO:0050892</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The cellular process in which a signal is conveyed to trigger a change in the activity or state of a cell. Signal transduction begins with reception of a signal, e.g. a ligand binding to a receptor or receptor activation by a stimulus such as light, and ends with regulation of a downstream cellular process, e.g. regulation of transcription or regulation of a metabolic process. Signal transduction covers signaling from receptors located on the surface of the cell, and signaling via molecules located within the cell. For signaling between cells, signal transduction is restricted to events at and within the receiving cell.</Detail>
      <Keyword>Signal transduction</Keyword>
      <Ontology_ID>GO:0007165</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of epinephrine.</Detail>
      <Keyword>Negative regulation of epinephrine secretion</Keyword>
      <Ontology_ID>GO:0032811</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process involved in the maintenance of an internal steady state of glucose within an organism or cell.</Detail>
      <Keyword>Glucose homeostasis</Keyword>
      <Ontology_ID>GO:0042593</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of adrenergic receptor protein signaling pathway activity. An adrenergic receptor signaling pathway is the series of molecular signals generated as a consequence of an adrenergic receptor binding to one of its physiological ligands.</Detail>
      <Keyword>Negative regulation of adrenergic receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0071878</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that decreases the frequency, rate or extent of the regulated release of insulin that contributes to the response of a cell to glucose.</Detail>
      <Keyword>Negative regulation of insulin secretion involved in cellular response to glucose</Keyword>
      <Ontology_ID>GO:0061179</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of calcium ion-dependent exocytosis.</Detail>
      <Keyword>Negative regulation of calcium ion-dependent exocytosis</Keyword>
      <Ontology_ID>GO:0045955</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that initiates the activity of the inactive enzyme protein kinase B.</Detail>
      <Keyword>Activation of protein kinase B activity</Keyword>
      <Ontology_ID>GO:0032148</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals generated as a consequence of an adrenergic receptor binding to its physiological ligand, followed by inhibition of adenylyl cyclase and a subsequent decrease in the concentration of cyclic AMP.</Detail>
      <Keyword>Inhibition of adenylate cyclase activity by adrenergic receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0071881</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways involving small molecules, any monomeric molecule of small relative molecular mass.</Detail>
      <Keyword>Small molecule metabolic process</Keyword>
      <Ontology_ID>GO:0044281</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process in which an epidermal growth factor receptor is activated via signaling events from a G-protein coupled receptor. This is an example of cross-talk between the EGFR and GPCR signaling pathways.</Detail>
      <Keyword>Epidermal growth factor receptor transactivation by G-protein coupled receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0035625</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of the directed movement of potassium ions (K+) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.</Detail>
      <Keyword>Positive regulation of potassium ion transport</Keyword>
      <Ontology_ID>GO:0043268</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A series of molecular signals within the cell that are mediated by a member of the Rho family of proteins switching to a GTP-bound active state.</Detail>
      <Keyword>Rho protein signal transduction</Keyword>
      <Ontology_ID>GO:0007266</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable hemostatic plug.</Detail>
      <Keyword>Platelet activation</Keyword>
      <Ontology_ID>GO:0030168</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of cytoskeletal structures comprising actin filaments and their associated proteins.</Detail>
      <Keyword>Actin cytoskeleton organization</Keyword>
      <Ontology_ID>GO:0030036</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of calcium ions via a voltage-gated calcium channel.</Detail>
      <Keyword>Negative regulation of calcium ion transport via voltage-gated calcium channel activity</Keyword>
      <Ontology_ID>GO:0051927</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of production of a cytokine.</Detail>
      <Keyword>Positive regulation of cytokine production</Keyword>
      <Ontology_ID>GO:0001819</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of lipids.</Detail>
      <Keyword>Negative regulation of lipid catabolic process</Keyword>
      <Ontology_ID>GO:0050995</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals generated as a consequence of an adrenergic receptor binding to its physiological ligand, followed by the activation of a MAP kinase.</Detail>
      <Keyword>Activation of MAPK activity by adrenergic receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0071883</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that increases the rate, frequency, or extent of the series of events that restore integrity to a damaged tissue, following an injury.</Detail>
      <Keyword>Positive regulation of wound healing</Keyword>
      <Ontology_ID>GO:0090303</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a hormone stimulus.</Detail>
      <Keyword>Cellular response to hormone stimulus</Keyword>
      <Ontology_ID>GO:0032870</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The directed, self-propelled movement of a cellular component without the involvement of an external agent such as a transporter or a pore.</Detail>
      <Keyword>Cellular component movement</Keyword>
      <Ontology_ID>GO:0006928</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals generated as a consequence of a G-protein coupled receptor binding to its physiological ligand.</Detail>
      <Keyword>G-protein coupled receptor protein signaling pathway</Keyword>
      <Ontology_ID>GO:0007186</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that decreases the frequency, rate or extent of the regulated release of norepinephrine.</Detail>
      <Keyword>Negative regulation of norepinephrine secretion</Keyword>
      <Ontology_ID>GO:0010700</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>298</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>299</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>297</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MGSLQPDAGNASWNGTEAPGGGARATPYSLQVTLTLVCLAGLLMLLTVFGNVLVIIAVFTSRALKAPQNLFLVSLASADILVATLVIPFSLANEVMGYWYFGKAWCEIYLALDVLFCTSSIVHLCAISLDRYWSITQAIEYNLKRTPRRIKAIIITVWVISAVISFPPLISIEKKGGGGGPQPAEPRCEINDQKWYVISSCIGSFFAPCLIMILVYVRIYQIAKRRTRVPPSRRGPDAVAAPPGGTERRPNGLGPERSAGPGGAEAEPLPTQLNGAPGEPAPAGPRDTDALDLEESSSSDHAERPPGPRRPERGPRGKGKARASQVKPGDSLPRRGPGATGIGTPAAGPGEERVGAAKASRWRGRQNREKRFTFVLAVVIGVFVVCWFPFFFTYTLTAVGCSVPRTLFKFFFWFGYCNSSLNPVIYTIFNHDFRRAFKKILCRGDRKRIV</Protein_Seq>
    <DNA_Seq>GCGCTCGGCGCCCACCAGGCGGACGCCCAGGAGAACCCCTGCCTCCGTCGCGGCTCCTGGAGAGCTGATCGTTCACCTGCCCCGGCCCGCCTGAGGACGGGGGTGCCTTCATGCGGCCCCCACACTCCTCACCCCGCCGCCGCCGCCGTCCCCGAGCTCCGCACAGTGCGCCCCAGCCCCAGCAGGGCGCACAACTTTGGAAGTCTCGCGGCGCTCCGAGAGGCGGCAGAGTCCGCGCCCCAGCCCCGGGCCGGGCCGGGCCAGAACCGCAGCGTCTGGGGGAAGCCAGAGAGTCGGTAATCGCTTCGGGGATGTAAGGCGACAGACATAGGACCCCCGAGCTCGCATCAGCACCCTTCGGCTGCCTCCCGGGGTGGGGGCGGGCCCCGCACACGGTAAGACCTCTTGCTTTCGCTCAGGCTCAAGATTCAAGATACAGATATTGATATGTATATATATATTTAATTTCCTGTCATCCTTCCAAGTTATCAGGCCACCGATGATTTTTGTTCTCCCTTCTTGAAGAATAAATCTCTCTTTACCCATCGGCTCTCCCTACTCTCTCCCGCCGCTTAGAAATAAAACTTGGCTGTATTAGGAGCTCGGAGCAAGAAGGCGCCCACCGAGAGCGTCTGAAGCGCGAGCCAGGCGCAGTTCGCGGGACCCGGGCCATGGGCCGCTAGCGGTCCTCCAGTTCGGGCCCGGCCTCCCTGCGGCCCCCTCCCTATGTGAGCCGCAGCCAGGCGAGCGGGGCGCCGGAGGAAGAGGAGGACCCACGGGCGCCGGGCCGGAAGGCAGCTGGCAGCAGGCCCAGGCCAGCGGGCGCCCGCGTTCATGTTCCGCCAGGAGCAGCCGTTGGCCGAGGGCAGCTTTGCGCCCATGGGCTCCCTGCAGCCGGACGCGGGCAACGCGAGCTGGAACGGGACCGAGGCGCCGGGGGGCGGCGCCCGGGCCACCCCTTACTCCCTGCAGGTGACGCTGACGCTGGTGTGCCTGGCCGGCCTGCTCATGCTGCTCACCGTGTTCGGCAACGTGCTCGTCATCATCGCCGTGTTCACGAGCCGCGCGCTCAAGGCGCCCCAAAACCTCTTCCTGGTGTCTCTGGCCTCGGCCGACATCCTGGTGGCCACGCTCGTCATCCCTTTCTCGCTGGCCAACGAGGTCATGGGCTACTGGTACTTCGGCAAGGCTTGGTGCGAGATCTACCTGGCGCTCGACGTGCTCTTCTGCACGTCGTCCATCGTGCACCTGTGCGCCATCAGCCTGGACCGCTACTGGTCCATCACACAGGCCATCGAGTACAACCTGAAGCGCACGCCGCGCCGCATCAAGGCCATCATCATCACCGTGTGGGTCATCTCGGCCGTCATCTCCTTCCCGCCGCTCATCTCCATCGAGAAGAAGGGCGGCGGCGGCGGCCCGCAGCCGGCCGAGCCGCGCTGCGAGATCAACGACCAGAAGTGGTACGTCATCTCGTCGTGCATCGGCTCCTTCTTCGCTCCCTGCCTCATCATGATCCTGGTCTACGTGCGCATCTACCAGATCGCCAAGCGTCGCACCCGCGTGCCACCCAGCCGCCGGGGTCCGGACGCCGTCGCCGCGCCGCCGGGGGGCACCGAGCGCAGGCCCAACGGTCTGGGCCCCGAGCGCAGCGCGGGCCCGGGGGGCGCAGAGGCCGAACCGCTGCCCACCCAGCTCAACGGCGCCCCTGGCGAGCCCGCGCCGGCCGGGCCGCGCGACACCGACGCGCTGGACCTGGAGGAGAGCTCGTCTTCCGACCACGCCGAGCGGCCTCCAGGGCCCCGCAGACCCGAGCGCGGTCCCCGGGGCAAAGGCAAGGCCCGAGCGAGCCAGGTGAAGCCGGGCGACAGCCTGCCGCGGCGCGGGCCGGGGGCGACGGGGATCGGGACGCCGGCTGCAGGGCCGGGGGAGGAGCGCGTCGGGGCTGCCAAGGCGTCGCGCTGGCGCGGGCGGCAGAACCGCGAGAAGCGCTTCACGTTCGTGCTGGCCGTGGTCATCGGAGTGTTCGTGGTGTGCTGGTTCCCCTTCTTCTTCACCTACACGCTCACGGCCGTCGGGTGCTCCGTGCCACGCACGCTCTTCAAATTCTTCTTCTGGTTCGGCTACTGCAACAGCTCGTTGAACCCGGTCATCTACACCATCTTCAACCACGATTTCCGCCGCGCCTTCAAGAAGATCCTCTGTCGGGGGGACAGGAAGCGGATCGTGTGAGGTTTCCGCTGGCGCCCGCGTAGACTCACGCTGACTGCAGGCAGCGGGGGGCATCGAGGGGTGCTTAGCCCCAGGGCACTCAGAAACCCGGGCGCTGCCTGCTCTGCGTTTCCTCGTCTGGGGTGGCTCTGCAGCCTCCTGCGGGCGGGCGTCTGCTGCTCCTACAAGGGAAGCTTCTTGCTGCCAGGCCCACACATCCCCAGTTGTTGGTTTGGCCACTCTTGACCTGGAGCCATCTTCCTAGTGGGCCACCCCTAATCACTATTGCTTCCTAAAGGTATTTTCACCCTCTTCGCCTGGTACAGCCCTCACAGCTCTTCAGAGCAAGCACTGGACTACAAGGGCATGGCTCACAAAAGGTTAATGGATGGGGGTTACCTAGCCCTGGCTAATTCCCCTTCCATTCCCAACTCTCTCTCTCTTTTTGAAGAAAAATGCTAAGGGCAGCCCTGCCTGCCCTCCCCATCCCCCGCTGTAAATATACACTATTTTTGATAGCACACATGGGGCCCCCATATCTCTTGGCCTTGGTTTTGATGTTGAAATCCTGGCCTTGGGAGAGATGCCTTCCAGGCAGACACAGCTGTCTGGTTCAGGCCAAGCCCCTTTGCAATGCAAGCCCTTTCTGGTGTTATGAAGTCCCTCTATGTCGTCGTTTTCACCAGCAACTGGTGACTGTCCCTTCGACACGGACCTGCTTTGAGATTTCCTGACAGGGAAAAGATTTCTGTCCATTTTTTTCCTGTGCCTAACAGCATAATTGCCTTTTCCTATGTAAATATTATGATGGTGGATCAAGACATAAGTAAATGAGCCTTTCTGCCTCACATCAGCCCTGTGTATAAAGCCATTATTCTCTGATGCACTGTTTGCCCCAGTAACTCACTTTAAAACCTCTCTTTCCAGTGTTCCCTCTCTCCCTCCAGGGCCACTGCTTGAAGAAGAATATGTATGTTTCTATCTTGTATGTCTGTGTGCCCCTCCTGCCCCGAAAGTGCTGACTATGGGGAAATCTTTTAGCTGCTGTTTTTAGACTCCAAGGAGTGGAAATTATGTGGAAGAAGCAAACCTGATACAATTTGCCCAAGGTAAACAGTTTGAAAAGACAAATGGGCCTGCCAAACTGTACAGTTTCTTCCCCAAGAGCTGTTAGGTATCAAAATGTTGTCCTTTCCCCCCTCCGTGCTTTTCTGGTTGAGATCATGTCATTGATGAACTGCCAAAGTCAGGGGAGGAGGGCAGAGACTTTGTGTTTACATCTGCATTTCTACATGTTTTAGACAGAGACAATTTAAGGCCTGCACTCTTATTTCACTAAAGAAAAACTAATGTCAGCACATGTTGCTAATGACAGTGGATTTTTTTTTAAATAAAAAAGTTTACAGATCAAATGTGAAATAAATATGAATGGAGTGGTCAAA</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Heart</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Spleen</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Lung</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Liver</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Brain</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Kidney</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Aorta</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Skeletal muscle</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cell membrane</CellLocal>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>ADRA2A</Gene_Name>
    <Gene_Alias>ADRA2R; ADRAR</Gene_Alias>
    <Gene_ID>150</Gene_ID>
    <Genbank_ACCN>NM_000681</Genbank_ACCN>
    <Protein_ACCN>NP_000672</Protein_ACCN>
    <HGNC_ID>281</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/150</Gene_URL>
    <UCSC_ID>uc001kzo.3</UCSC_ID>
    <EMBL_ID>ENSG00000150594</EMBL_ID>
  </Gene>
  <Disease_List>
    <Disease>
      <Disease_Name>Attention Deficit Hyperactivity Disorder</Disease_Name>
      <Disease_Detail>Attention Deficit Hyperactivity Disorder</Disease_Detail>
      <Disease_DB>ATT002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/attention_deficit_hyperactivity_disorder?search=ADRA2A#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Orthostatic Intolerance</Disease_Name>
      <Disease_Detail>Orthostatic Intolerance</Disease_Detail>
      <Disease_DB>ORT004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/orthostatic_intolerance?search=ADRA2A#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Irritable Bowel Syndrome</Disease_Name>
      <Disease_Detail>Irritable Bowel Syndrome</Disease_Detail>
      <Disease_DB>IRR002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/irritable_bowel_syndrome?search=ADRA2A#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Constipation</Disease_Name>
      <Disease_Detail>Constipation</Disease_Detail>
      <Disease_DB>CNS004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/constipation?search=ADRA2A#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Systolic Heart Failure</Disease_Name>
      <Disease_Detail>Systolic Heart Failure</Disease_Detail>
      <Disease_DB>SYS003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/systolic_heart_failure?search=ADRA2A#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Obesity</Disease_Name>
      <Disease_Detail>Obesity</Disease_Detail>
      <Disease_DB>OBS005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/obesity?search=ADRA2A#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Schizophrenia</Disease_Name>
      <Disease_Detail>Schizophrenia</Disease_Detail>
      <Disease_DB>SCH015</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/schizophrenia?search=ADRA2A#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Motion Sickness</Disease_Name>
      <Disease_Detail>Motion Sickness</Disease_Detail>
      <Disease_DB>MTN003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/motion_sickness?search=ADRA2A#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Cholera</Disease_Name>
      <Disease_Detail>Cholera</Disease_Detail>
      <Disease_DB>CHL014</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/cholera?search=ADRA2A#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Gilles De La Tourette Syndrome</Disease_Name>
      <Disease_Detail>Gilles De La Tourette Syndrome</Disease_Detail>
      <Disease_DB>GLL008</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/gilles_de_la_tourette_syndrome?search=ADRA2A#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>NMR STRUCTURE OF T3-I2, A 32 RESIDUE PEPTIDE FROM THE ALPHA-2A ADRENERGIC RECEPTOR</PDB_Title>
      <PDB_ID>1HOF</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore.do?structureId=1HOF</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>NMR structure of the second intracellular loop of the alpha 2A adrenergic receptor: evidence for a novel cytoplasmic helix.</PubMed_Title>
      <Author>Chung DA, et al.</Author>
      <Journal>(2002) Biochemistry 41: 3596-3604</Journal>
      <PubMed_ID>11888275</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>NMR STRUCTURE OF D130I MUTANT T3-I2, A 32 RESIDUE PEPTIDE FROM THE ALPHA 2A ADRENERGIC RECEPTOR</PDB_Title>
      <PDB_ID>1HOD</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore.do?structureId=1HOD</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>NMR structure of the second intracellular loop of the alpha 2A adrenergic receptor: evidence for a novel cytoplasmic helix.</PubMed_Title>
      <Author>Chung DA, et al.</Author>
      <Journal>(2002) Biochemistry 41: 3596-3604</Journal>
      <PubMed_ID>11888275</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>NMR STRUCTURE OF T3-I2, A 32 RESIDUE PEPTIDE FROM THE ALPHA-2A ADRENERGIC RECEPTOR</PDB_Title>
      <PDB_ID>1HLL</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore/explore.do?structureId=1HLL</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>NMR structure of the second intracellular loop of the alpha 2A adrenergic receptor: evidence for a novel cytoplasmic helix.</PubMed_Title>
      <Author>Chung DA, et al.</Author>
      <Journal>(2002) Biochemistry 41: 3596-3604</Journal>
      <PubMed_ID>11888275</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>BEST 20 NMR CONFORMERS OF D130I MUTANT T3-I2, A 32 RESIDUE PEPTIDE FROM THE ALPHA 2A ADRENERGIC RECEPTOR</PDB_Title>
      <PDB_ID>1HO9</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.rcsb.org/pdb/explore/explore.do?structureId=1HO9</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>NMR structure of the second intracellular loop of the alpha 2A adrenergic receptor: evidence for a novel cytoplasmic helix.</PubMed_Title>
      <Author>Chung DA, et al.</Author>
      <Journal>(2002) Biochemistry 41: 3596-3604</Journal>
      <PubMed_ID>11888275</PubMed_ID>
    </PDB>
  </PDB_List>
  <Fold>
    <SCOP_Class>Peptides</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.ba.bab.b.b.b.html</SCOP_URL>
  </Fold>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD00170297</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD00170351</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03050002</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03070001</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2012-05-31</Create_Date>
</Organism_Record>